About E&I
Company Profile
Scope of Studies
Our Board
Contact Us
Services
Fees
Translation Services
Contracting with Us
Our Compliance Policy
Approval Stipulations/Conditions
Investigators / Sites
About Investigator Section
Initial Submissions
Joining a Multi-site Study
Submitting Single-site Studies
Submitting Investigator Initiated Studies
Other Review Categories
Individual/Emergency/HUD
Biological Specimens
Post Approval Reporting Obligations
Modifications/Changes in Research
Reporting Violations/Problems
New Information
Continuing Review
Recruitment / Advertising
Closing a Study
Investigator Training
SBER Section
Sponsor / CRO
About Sponsor Section
Initial Sponsor Submission
Multi-site Studies
Protocol Amendments and Revisions
Reporting Obligations/Agreements
Unanticipated Problems
New Information
Continuing Review
Closing a Study
Research Participants
Frequently Asked Questions
About Participant Section
Resources
Contracting with E&I
IRB Reliance Agreements
Forms
Search
Home
About E&I
Contact Us
Guidance
NEW Revised Common Rule
Revisions to the Common Rule and Their Application
Overview of Changes to Common Rule
Revisions to the Common Rule: Frequently Asked Questions
Device Studies
Device Basics
NSR vs SR
E&I NSR Policy
Risk Evaluation Tool
Humanitarian Devices
Humanitarian Devices Basics
HUD Part 812.100
Informed Consent (IC)
IC Overview
IC Process
IRB Review
Is IRB Review Required?
Types of Review Available
IRB Review Exemption
More on Expedited Review
Protocol Design Issues
Non-Local Issues
Risk Analysis
Multi-center Studies
HIPAA Requirements and Waivers
HIPAA Requirements and Waivers
E&I's HIPAA Policy
Non-Invasive Research
Clinical Effectiveness Research (CER)
Outcomes Research
Qualitative Research
Program & Responsibility
FWA Basics
FWA Policy Overview
FWA Sample SOP
SBER-Soc, Behav, Educ, Eval
Subject Protection
Defining an HRPP
E&I's HRPP
E&I's Conflict of Interest Policy
E&I's Compliance Policy / Registration
E&I's PI / Site Training Requirements
Basics of HRPP Development
Regulatory Guidance
FDA Guidance
OHRP Guidance
Belmont Report
State Regulations
Resources
Regulation
Pharmaceuticals News
Contact Us
To contact E&I:
CLOAKING
(800) 472-3241
Corporate Office
304 SE Third Street
Lees Summit, Missouri 64063
Last Updated ( DATE_FORMAT_LC2 )
